Liver Transplantation for Classical Maple Syrup Urine Disease: Long-Term Follow-Up in 37 Patients and Comparative United Network for Organ Sharing Experience - 08/12/11
1, ⁎ 
, D. Holmes Morton, MD 2, Rakesh Sindhi, MD 1, Kyle Soltys, MD 1, Navdeep Nayyar, MD 1, Geoffrey Bond, MD 1, Diana Shellmer, PhD 5, Benjamin Shneider, MD 5, Jerry Vockley, MD 6, Kevin A. Strauss, MD , 2, 3, 4Reprint requests: George V. Mazariegos, MD, FACS, Hillman Center for Pediatric Transplantation, Children’s Hospital of Pittsburgh of UPMC, One Children’s Hospital Drive, 4401 Penn Avenue, Faculty Pavilion, Floor 6, Room 6141, Pittsburgh, PA 15224.Abstract |
Objective |
To assess clinical and neurocognitive function in children who have undergone liver transplantation for classical maple syrup urine disease (MSUD).
Study design |
A total of 35 patients with classical MSUD (age 9.9±7.9 years) underwent liver transplantation between 2004 and 2009. Six patients donated their liver to recipients without MSUD (“domino” transplant). We analyzed clinical outcomes for our cohort and 17 additional cases from the national United Network for Organ Sharing registry; 33 patients completed IQ and adaptive testing before transplantation, and 14 completed testing 1 year later.
Results |
Patient and graft survival were 100% at 4.5±2.2 years of follow-up. Liver function was normal in all patients. Branched-chain amino acid levels were corrected within hours after surgery and remained stable, with leucine tolerance increasing more than 10-fold. All domino transplant recipients were alive and well with normal branched-chain amino acid homeostasis at the time of this report. Patient and graft survival for all 54 patients with MSUD undergoing liver transplantation in the United States during this period were 98% and 96%, respectively. One-third of our patients were mentally impaired (IQ ≤ 70) before transplantation, with no statistically significant change 1 year later.
Conclusion |
Liver transplantation is an effective long-term treatment for classical MSUD and may arrest brain damage, but will not reverse it.
Le texte complet de cet article est disponible en PDF.Mots-clés : BCAA, BCKDH, MSUD, UNOS
Plan
| Funded by charitable contributions from the Old Order Mennonite and Amish communities to the nonprofit Clinic for Special Children and the Hillman Foundation. The authors and affiliated clinicians had sole responsibility for the clinical care described herein, the development of the manuscript, and interpretation of the data and outcomes, with no role from any external funding sponsors. The authors declare no conflicts of interest. |
Vol 160 - N° 1
P. 116 - janvier 2012 Retour au numéro
Article précédent
- B-Type Natriuretic Peptide and Rebound during Treatment for Persistent Pulmonary Hypertension
- Daniel C. Vijlbrief, Manon J.N.L. Benders, Hans Kemperman, Frank van Bel, Willem B. de Vries
- Body Composition Abnormalities in Long-Term Survivors of Pediatric Hematopoietic Stem Cell Transplantation
- Sogol Mostoufi-Moab, Jill P. Ginsberg, Nancy Bunin, Babette S. Zemel, Justine Shults, Meena Thayu, Mary B. Leonard
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?